Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.53 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GPR183 | P32249 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11747939 | 0.83 | AGTR2 (0.53) | AGTR2NPC1KMT2AGPR183AGTR1 | |
| SCHEMBL23315326 | 0.83 | AGTR2 (0.53) | AGTR2AGTR1 | |
| SCHEMBL23315583 | 0.81 | NPC1 (0.62) | AGTR2NPC1KMT2AGPR183AGTR1 | |
| SCHEMBL8964453 | 0.81 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL8964079 | 0.81 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL21796225 | 0.79 | AGTR2 (0.66) | AGTR2AGTR1 | |
| SCHEMBL16039389 | 0.79 | AGTR2 (0.52) | AGTR2GPR183AGTR1 | |
| SCHEMBL23315204 | 0.77 | AGTR2 (0.51) | AGTR2GPR183AGTR1 | |
| SCHEMBL17607347 | 0.77 | ACACB (0.49) | AGTR2NPC1KMT2AGPR183AGTR1 | |
| SCHEMBL5132181 | 0.76 | AGTR2 (0.68) | AGTR2NPC1MEN1KMT2AAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551950-B2 | Method of treatment or prophylaxis of inflammatory pain | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-10-08 | — | — | US | disclosed |
| US-20100292159-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN | UNIVERSITY OF QUEENSLAND (AU) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292159-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN | AGTR2, AGTR1, BDKRB2 | AGTR2 1/4885NPC1 4122/4885RAB9A 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.